Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) has been given a consensus recommendation of “Buy” by the nine research firms that are covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, two have given a hold recommendation and six have issued a buy recommendation on the company. The average 1-year target price among analysts that have issued a report on the stock in the last year is $24.47.
Several analysts have recently issued reports on SYRS shares. Zacks Investment Research cut Syros Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Wednesday, October 11th. ValuEngine cut Syros Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Friday, September 22nd. Cann reiterated a “buy” rating and issued a $28.00 price objective on shares of Syros Pharmaceuticals in a research note on Monday, August 21st. Roth Capital started coverage on Syros Pharmaceuticals in a research note on Monday, October 23rd. They issued a “neutral” rating and a $15.00 price objective on the stock. Finally, JMP Securities upgraded Syros Pharmaceuticals from a “market perform” rating to an “outperform” rating and set a $33.00 price objective on the stock in a research note on Thursday, September 28th.
Shares of Syros Pharmaceuticals (NASDAQ:SYRS) traded down 1.53% on Wednesday, reaching $15.41. The company had a trading volume of 84,072 shares. The firm’s market capitalization is $404.67 million. Syros Pharmaceuticals has a 12 month low of $10.22 and a 12 month high of $17.89. The firm’s 50 day moving average is $16.09 and its 200 day moving average is $16.09.
Syros Pharmaceuticals (NASDAQ:SYRS) last announced its quarterly earnings data on Wednesday, August 9th. The company reported ($0.52) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.55) by $0.03. On average, equities research analysts expect that Syros Pharmaceuticals will post ($2.09) earnings per share for the current fiscal year.
In other Syros Pharmaceuticals news, Director Richard A. Young sold 3,282 shares of the firm’s stock in a transaction on Monday, August 14th. The stock was sold at an average price of $22.00, for a total value of $72,204.00. Following the sale, the director now directly owns 420,101 shares in the company, valued at $9,242,222. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Eric R. Olson sold 2,500 shares of the firm’s stock in a transaction on Monday, August 7th. The shares were sold at an average price of $23.59, for a total value of $58,975.00. Following the completion of the sale, the insider now owns 2,500 shares in the company, valued at $58,975. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 6,332 shares of company stock worth $140,012. 33.60% of the stock is owned by insiders.
A number of institutional investors have recently bought and sold shares of the business. FMR LLC raised its stake in Syros Pharmaceuticals by 11.9% in the second quarter. FMR LLC now owns 3,926,998 shares of the company’s stock valued at $63,185,000 after buying an additional 418,061 shares in the last quarter. Redmile Group LLC raised its stake in Syros Pharmaceuticals by 2.2% in the second quarter. Redmile Group LLC now owns 973,260 shares of the company’s stock valued at $15,660,000 after buying an additional 20,520 shares in the last quarter. Vanguard Group Inc. raised its stake in Syros Pharmaceuticals by 189.6% in the second quarter. Vanguard Group Inc. now owns 382,603 shares of the company’s stock valued at $6,156,000 after buying an additional 250,507 shares in the last quarter. State Street Corp raised its stake in Syros Pharmaceuticals by 176.7% in the second quarter. State Street Corp now owns 169,497 shares of the company’s stock valued at $2,728,000 after buying an additional 108,250 shares in the last quarter. Finally, AWM Investment Company Inc. raised its stake in Syros Pharmaceuticals by 155.8% in the second quarter. AWM Investment Company Inc. now owns 121,624 shares of the company’s stock valued at $1,957,000 after buying an additional 74,074 shares in the last quarter. Institutional investors own 59.69% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: “Brokerages Set Syros Pharmaceuticals, Inc. (SYRS) Target Price at $24.47” was reported by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are accessing this piece on another domain, it was illegally copied and reposted in violation of United States and international copyright law. The original version of this piece can be viewed at https://ledgergazette.com/2017/11/13/brokerages-set-syros-pharmaceuticals-inc-syrs-target-price-at-24-47.html.
About Syros Pharmaceuticals
Syros Pharmaceuticals, Inc is a biopharmaceutical company. The Company offers a gene control platform designed to analyze the unexploited region of deoxyribonucleic acid (DNA) in human disease tissue to identify and drug targets linked to genomically defined patient populations. The Company is focused on developing treatments for cancer and immune-mediated diseases and is building a pipeline of gene control medicines.
Receive News & Ratings for Syros Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syros Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.